We report a 16-year-old man with severe heart failure due to idiopathic pulmonary arterial hypertension (IPAH) 
Introduction

Idiopathic pulmonary arterial hypertension (IPAH) is a rare but life-threatening disease, characterized by progressive pulmonary hypertension, that ultimately leads to right ventricular failure and death (1). Traditionally, treatment is based on the administration of vasodilators, particularly calcium channel blockers. However, calcium channel blockers are effective in only a limited number of patients (2). Previous reports have shown that beraprost, a prostacyclin analog, reduces pulmonary vascular resistance and improves exercise capacity and ventilatory efficiency in patients with
IPAH (3) (4) (5) (6) . Sarpogrelate, a serotonin receptor antagonist also attenuates the development of pulmonary artery hypertension in both clinical and experimental settings (7) (8) (9) (10) . However, there is no report on the combination therapy of beraprost and sarpogrelate for IPAH patients.
Recently, sildenafil, a phosphodiesterase inhibitor (PDE)-5 approved for the treatment of erectile dysfunction, has been investigated for the treatment of IPAH (11) (12) (13) After starting sildenafil treatment, the patient's condition
F i g u r e 2 . Ch e s t r o e n t g e n o g r a p h i c c h a n g e s . T h e c a r d i o -t h o r a c i c r a t i o ( CT R) i n c r e a s e d 3 mo n t h s a f t e r t h e c o mb i n a t i o n t h e r a p y o f b e r a p r o s t a n d s a p r o g l e r a t e ( B ) c o mp a r e d t o t h a t o n t h e f i r s t a dmi n i s t r a t i o n ( A) , b u t d e c r e a s e d a f t e r c h a n g i n g t o s i l d e n a f i l ( C) .
dramatically improved, and he had no side effect from sildenafil. After 1 month of treatment, his 6-minute walking distance increased from 160 m to 420 m and his NYHA classification changed from III to II (Fig. 1) . PVR, mean right atrial pressure, uric acid, and BNP were all decreased; CI also improved 1 month after switching to sildenafil, and these parameters did not change at 3 months after starting sildenafil (Fig. 1) . Chest X-ray showed marked cardiomegaly and decreased CTR (Fig. 2) . ECG showed right ventricular (RV) hypertrophy and decreased right axis deviation (Fig. 3) . Echocardiography showed decreased RV pressure overload and decrease of mild pericardial effusion (Fig. 4) .
Discussion
In (19, 20) F i g u r e 4 . E c h o c a r d i o g r a p h i c c h a n g e s . B e f o r e s i l d e n a f i l a d mi n i s t r a t i o n , t h e i n t e r v e n t r i c u l a r s e pt u m ( I VS ) wa s f l a t t e n e d a n d mi l p e r i c a r d i a l e f f u s i o n wa s s e e n a t t h e e n d -d i a s t o l i c a n d t h e e n d -s y st o l i c p h a s e s ( A) . At 1 mo n t h a f t e r t h e t r e a t me n t , p e r i c a r d i a l e f f u s i o n d i s a p p e a r e d a n d t h e f l a t t e ni n g o f I VS a l s o d i s a p p e a r e d a t t h e e n d -d i a s t o l i c p h a s e ( B ) . E n d -d i a s t , e n d -d i a s t o l i c p h a s e ; E n d -s y s t ,  e n d -s y s t o l i c p h a s (25) .
. However, bosentan was not used in our hospital at that time. Sildenafil has been shown to have beneficial effects in patients with IPAH (11-13). However, it is not indicated for the treatment of IPAH in Japan. Serotonin (5-HT) released from blood platelets accelerates plate-
F i g u r e 3 . E l e c t r o c a r d i o g r a p h i c c h a n g e s . Ri g h t a x i s d e v i a t i o n p r o g r e s s e d o n t h e t h i r d a d mi s s i o n ( B ) c o mp a r e d t o t h e f i r s t a d mi s s i o n ( A) ; a f t e r 1 -mo n t h o f s i l d e n a f i l a d mi n i s t r a t i o n , i t d e c r e a s e d ( C) .
Previous studies have also discussed combination therapy for IPAH. Combination therapy with sildenafil and beraprost showed additive effects to increase plasma cAMP and cGMP levels in rats (26) . Sildenafil therapy may be beneficial to patients with PAH receiving long-term infusion of epoprostenol (27) . In Japan, Kataoka et al (28, 29) 
